Abstract

Bhupesh Yadav, Dr. Rajesh Mujariya, Dr. Manjeet Singh

ABSTRACT

Mouth dissolving tablets (MDTs) offer a patient-friendly and convenient dosage form for the administration of anti-allergic drugs. This review article highlights the formulation development, evaluation, and potential applications of MDTs in the field of allergy treatment. MDTs address the challenges associated with swallowing difficulties, particularly in pediatric and geriatric populations, and enhance patient compliance and convenience. The review discusses various formulation approaches for MDTs, including direct compression, wet granulation, dry granulation, lyophilization, sublimation, spray drying, molding, and orodispersible film technology. Excipient selection plays a crucial role in taste masking, disintegration, and stability of MDTs. Superdisintegrants, binder agents, sweeteners, flavoring agents, disintegration enhancers, and filler and diluent agents are commonly used to optimize the formulation. Evaluation parameters such as disintegration time, wetting time, friability, drug content uniformity, in vitro drug release, and stability are important for ensuring the quality and performance of MDTs. Taste masking and palatability challenges are addressed through the use of flavoring agents, sweeteners, encapsulation or coating techniques, and complexation approaches. The review emphasizes the importance of scale-up considerations, including equipment compatibility, dosage uniformity, process efficiency, compression and disintegration challenges, packaging considerations, and adherence to quality control and regulatory requirements. Future prospects and potential applications of MDTs for anti-allergic drugs are explored, including allergen-specific formulations, combination therapies, controlled release formulations, personalized medicine approaches, pediatric and geriatric formulations, allergen-specific immunotherapy, and digital integration for monitoring and adherence. In conclusion, MDTs have emerged as a promising dosage form for the administration of anti-allergic drugs. Further research and development efforts, along with regulatory compliance, are required to fully exploit the potential benefits of MDTs in allergy treatment and to improve patient outcomes and satisfaction.